Trial Profile
Impact of alogliptin on coronary flow reserve evaluated by magnetic resonance imaging
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2017
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Glimepiride
- Indications Angina pectoris; Coronary artery disease; Myocardial infarction; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 20 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
- 18 Nov 2013 Status changed from recruiting to completed.
- 29 Jun 2012 New trial record